Effect of tadalafil on penile nitric oxide synthase and corporal smooth muscle in rats under dutasteride treatment

References

• Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin N Am. 2016;43(3):289–297.
   PubMed Web of Science ®Google Scholar
• Lee SWH, Chan EMC, Lai YK. The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. Sci Rep. 2017;7(1):7984.
   PubMedGoogle Scholar
• Liu L, Zhao S, Li F, et al. Effect of 5alpha-reductase inhibitors on sexual function: a meta-analysis and systematic review of randomized controlled trials. J Sex Med. 2016;13(9):1297–1310.
   PubMed Web of Science ®Google Scholar
• Erdemir F, Harbin A, Hellstrom WJ. 5-alpha reductase inhibitors and erectile dysfunction: the connection. J Sex Med. 2008;5(12):2917–2924.
   PubMed Web of Science ®Google Scholar
• Maeda T, Kikuchi E, Hasegawa M, et al. A prospective longitudinal survey of erectile function status in symptomatic benign prostatic hyperplasia patients treated with dutasteride. Aging Male. 2016;19(2):111–116.
   PubMed Web of Science ®Google Scholar
• Harris G, Azzolina B, Baginsky W, et al. Identification and selective inhibition of an isozyme of steroid 5 alpha-reductase in human scalp. PNAS. 1992;89(22):10787–10791.
   PubMed Web of Science ®Google Scholar
• Bramson HN, Hermann D, Batchelor KW, et al. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther. 1997;282(3):1496–1502.
   PubMed Web of Science ®Google Scholar
• Andriole GL, Kirby R. Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol. 2003;44(1):82–88.
   PubMed Web of Science ®Google Scholar
• Qian X, Yu G, Qian Y, et al. Efficacy of 5 α-reductase inhibitors for patients with large benign prostatic hyperplasia (> 80 mL) after transurethral resection of the prostate. Aging Male. 2015;18(4):238–243.
   PubMed Web of Science ®Google Scholar
• Clark RV, Hermann DJ, Cunningham GR, et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004;89(5):2179–2184.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60(3):434–441.
   PubMed Web of Science ®Google Scholar
• Traish A, Haider KS, Doros G, et al. Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction. Horm Mol Biol Clin Investig. 2017;30(3):1–16.
   Web of Science ®Google Scholar
• Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. The urologic clinics of North America. Urol Clin North Am. 2005;32(4):379–395.
   PubMed Web of Science ®Google Scholar
• Giuliano F, Rampin O. Neural control of erection. Physiol Behav. 2004;83(2):189–201.
   PubMed Web of Science ®Google Scholar
• Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43(2):109–142.
   PubMed Web of Science ®Google Scholar
• Park KH, Kim SW, Kim KD, et al. Effects of androgens on the expression of nitric oxide synthase mRNAs in rat corpus cavernosum. BJU Int. 1999;83(3):327–333.
   PubMed Web of Science ®Google Scholar
• Pinsky MR, Gur S, Tracey AJ, et al. The effects of chronic 5-alpha-reductase inhibitor (dutasteride) treatment on rat erectile function. J Sex Med. 2011;8(11):3066–3074.
   PubMed Web of Science ®Google Scholar
• Oztekin CV, Gur S, Abdulkadir NA, et al. Incomplete recovery of erectile function in rat after discontinuation of dual 5-alpha reductase inhibitor therapy. J Sex Med. 2012;9(7):1773–1781.
   PubMed Web of Science ®Google Scholar
• Huang SA, Lie JD. Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction. Peer Rev J Formul Manage. 2013;38(7):407–419.
   Google Scholar
• Lue TF. Erectile dysfunction. N Engl J Med. 2000;342(24):1802–1813.
   PubMed Web of Science ®Google Scholar
• Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998;338(20):1397–1404.
   PubMed Web of Science ®Google Scholar
• Padma-Nathan H, McMurray JG, Pullman WE, et al. On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res. 2001;13(1):2–9.
   PubMed Web of Science ®Google Scholar
• Xu WD, Liu ZY, Ye HM, et al. [Efficacy and safety of long-term small-dose tadalafil in the treatment of erectile dysfunction]. Zhonghua Nan ke Xue. 2011;17(6):531–534.
   PubMedGoogle Scholar
• Gratzke C, Bachmann A, Descazeaud A, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015;67(6):1099–1109.
   PubMed Web of Science ®Google Scholar
• Glina S, Roehrborn CG, Esen A, et al. Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride. J Sex Med. 2015;12(1):129–138.
   PubMed Web of Science ®Google Scholar
• Ozkidik M, Gokce MI, Yaman O. Efficacy of tadalafil treatment on erectile dysfunction in patients under dutasteride treatment: a prospective non-randomized comparative study. Turk J Urol. 2018;44(4):294–297.
   PubMed Web of Science ®Google Scholar
• Sung HH, Yu J, Kang SJ, Chae MR, et al. Persistent erectile dysfunction after discontinuation of 5-alpha reductase inhibitor therapy in rats depending on the duration of treatment. World J Mens Health. 2019;37(2):240–248.
   PubMedGoogle Scholar
• Ferrini MG, Rivera S, Moon J, et al. The genetic inactivation of inducible nitric oxide synthase (iNOS) intensifies fibrosis and oxidative stress in the penile corpora cavernosa in type 1 diabetes. J Sex Med. 2010;7(9):3033–3044.
   PubMed Web of Science ®Google Scholar
• Vernet D, Ferrini MG, Valente EG, et al. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie’s fibrotic plaque and in its rat model. Nitric Oxide Biol Chem. 2002;7(4):262–276.
   PubMed Web of Science ®Google Scholar
• Ferrini MG, Vernet D, Magee TR, et al. Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide Biol Chem. 2002;6(3):283–294.
   PubMed Web of Science ®Google Scholar
• Ferrini MG, Davila HH, Kovanecz I, et al. Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology. 2006;68(2):429–435.
   PubMed Web of Science ®Google Scholar
• Da Silva MHA, Medeiros JL, Jr., Costa WS, et al. Effects of the dutasteride and sildenafil association in the penis of a benign prostatic hyperplasia animal model. Aging Male. [cited 2019 Aug 20]; [7 p.]. DOI:10.1080/13685538.2019.1653839
   Web of Science ®Google Scholar
• Gooren LJ, Saad F. Recent insights into androgen action on the anatomical and physiological substrate of penile erection. Asian J Androl. 2006;8(1):3–9.
   PubMed Web of Science ®Google Scholar
• Traish AM, Park K, Dhir V, et al. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology. 1999;140(4):1861–1868.
   PubMed Web of Science ®Google Scholar
• Ahn GJ, Chung HK, Lee CH, Kang KK, et al. Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical diabetogenesis. Asian J Androl. 2009;11(4):435–442.
   PubMed Web of Science ®Google Scholar
• Casabe A, Roehrborn CG, Da Pozzo LF, et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol. 2014;191(3):727–733.
   PubMed Web of Science ®Google Scholar
• Park H, Park N. 1092 Combination therapy with dutasteride and tadalafil in men with moderate-to-severe benign prostatic hyperplasia. Eur Urol Suppl. 2013;12(1):e1092.
   Google Scholar